J Neurosci Nurs. 2022 Feb 1;54(1):19-22. doi: 10.1097/JNN.0000000000000625.
Enteral nimodipine provides a neuroprotective effect in patients who have experienced an aneurysmal subarachnoid hemorrhage (aSAH). Nimodipine remains the only US Food and Drug Administration-approved medication for aSAH. CONTENT: Nimodipine has been prescribed for patients with aSAH; however, little is known about factors to consider regarding dosing or patient-specific variables that may affect tolerability to nimodipine. Clinical impact of dose or dosing frequency changes has also been much debated based on risk of hypotension with currently approved dosing regimens. CONCLUSION: This review article addresses factors to consider for dosing and administration, pharmacokinetic and pharmacogenetic impact on nimodipine, and, finally, drug interaction considerations to assess as patients are initiated on enteral nimodipine for aSAH.
肠内尼莫地平可在经历蛛网膜下腔出血（aSAH）的患者中提供神经保护作用。尼莫地平仍然是唯一获得美国食品和药物管理局批准用于 aSAH 的药物。内容：尼莫地平已开给 aSAH 患者使用；然而，关于剂量或可能影响尼莫地平耐受性的患者特定变量，我们知之甚少。基于目前批准的剂量方案发生低血压的风险，关于剂量或给药频率变化的临床影响也存在很多争议。结论：本文综述了考虑剂量和给药的因素、对尼莫地平的药代动力学和药物遗传学影响，以及在开始使用肠内尼莫地平治疗 aSAH 时要评估的药物相互作用注意事项。
